Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Results of a Phase II Randomized Controlled Study

James D Brandt, Kenneth Sall, Harvey DuBiner, Robert Benza, Yair Alster, Gary Walker, Charles P. Semba

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. Design: Parallel-arm, multicenter, double-masked, randomized, controlled trial. Participants: One hundred thirty adult OAG or OHT patients. Methods: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5% solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins. Main Outcome Measures: The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95% confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs). Results: A mean reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5% of patients at 6 months. Conclusions: Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - Dec 22 2015

Fingerprint

Intraocular Pressure
Timolol
Ocular Hypertension
Open Angle Glaucoma
Ophthalmic Solutions
Bimatoprost
Prostaglandins
Randomized Controlled Trials
Placebos
Outcome Assessment (Health Care)
Confidence Intervals

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Results of a Phase II Randomized Controlled Study. / Brandt, James D; Sall, Kenneth; DuBiner, Harvey; Benza, Robert; Alster, Yair; Walker, Gary; Semba, Charles P.

In: Ophthalmology, 22.12.2015.

Research output: Contribution to journalArticle

Brandt, James D ; Sall, Kenneth ; DuBiner, Harvey ; Benza, Robert ; Alster, Yair ; Walker, Gary ; Semba, Charles P. / Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Results of a Phase II Randomized Controlled Study. In: Ophthalmology. 2015.
@article{4e7d0bee6acf4e118fc98c09c9f99280,
title = "Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Results of a Phase II Randomized Controlled Study",
abstract = "Purpose: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. Design: Parallel-arm, multicenter, double-masked, randomized, controlled trial. Participants: One hundred thirty adult OAG or OHT patients. Methods: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5{\%} solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins. Main Outcome Measures: The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95{\%} confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs). Results: A mean reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5{\%} of patients at 6 months. Conclusions: Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP.",
author = "Brandt, {James D} and Kenneth Sall and Harvey DuBiner and Robert Benza and Yair Alster and Gary Walker and Semba, {Charles P.}",
year = "2015",
month = "12",
day = "22",
doi = "10.1016/j.ophtha.2016.04.026",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Results of a Phase II Randomized Controlled Study

AU - Brandt, James D

AU - Sall, Kenneth

AU - DuBiner, Harvey

AU - Benza, Robert

AU - Alster, Yair

AU - Walker, Gary

AU - Semba, Charles P.

PY - 2015/12/22

Y1 - 2015/12/22

N2 - Purpose: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. Design: Parallel-arm, multicenter, double-masked, randomized, controlled trial. Participants: One hundred thirty adult OAG or OHT patients. Methods: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5% solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins. Main Outcome Measures: The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95% confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs). Results: A mean reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5% of patients at 6 months. Conclusions: Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP.

AB - Purpose: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. Design: Parallel-arm, multicenter, double-masked, randomized, controlled trial. Participants: One hundred thirty adult OAG or OHT patients. Methods: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5% solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins. Main Outcome Measures: The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95% confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs). Results: A mean reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5% of patients at 6 months. Conclusions: Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP.

UR - http://www.scopus.com/inward/record.url?scp=84964921522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964921522&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2016.04.026

DO - 10.1016/j.ophtha.2016.04.026

M3 - Article

C2 - 27157843

AN - SCOPUS:84964921522

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -